<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32539528</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1535-7228</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>178</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>The American journal of psychiatry</Title>
          <ISOAbbreviation>Am J Psychiatry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antibodies From Children With PANDAS Bind Specifically to Striatal Cholinergic Interneurons and Alter Their Activity.</ArticleTitle>
        <Pagination>
          <StartPage>48</StartPage>
          <EndPage>64</EndPage>
          <MedlinePgn>48-64</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2020.19070698</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE">Pediatric obsessive-compulsive disorder (OCD) sometimes appears rapidly, even overnight, often after an infection. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, or PANDAS, describes such a situation after infection with <i>Streptococcus pyogenes</i>. PANDAS may result from induced autoimmunity against brain antigens, although this remains unproven. Pilot work suggests that IgG antibodies from children with PANDAS bind to cholinergic interneurons (CINs) in the striatum. CIN deficiency has been independently associated with tics in humans and with repetitive behavioral pathology in mice, making it a plausible locus of pathology. The authors sought to replicate and extend earlier work and to investigate the cellular effects of PANDAS antibodies on cholinergic interneurons.</AbstractText>
          <AbstractText Label="METHODS">Binding of IgG to specific neurons in human and mouse brain slices was evaluated ex vivo after incubation with serum from 27 children with rigorously characterized PANDAS, both at baseline and after intravenous immunoglobulin (IVIG) treatment, and 23 matched control subjects. Binding was correlated with symptom measures. Neural activity after serum incubation was assessed in mouse slices using molecular markers and electrophysiological recording.</AbstractText>
          <AbstractText Label="RESULTS">IgG from children with PANDAS bound to CINs, but not to several other neuron types, more than IgG from control subjects, in three independent cohorts of patients. Post-IVIG serum had reduced IgG binding to CINs, and this reduction correlated with symptom improvement. Baseline PANDAS sera decreased activity of striatal CINs, but not of parvalbumin-expressing GABAergic interneurons, and altered their electrophysiological responses, in acute mouse brain slices. Post-IVIG PANDAS sera and IgG-depleted baseline sera did not alter the activity of striatal CINs.</AbstractText>
          <AbstractText Label="CONCLUSIONS">These findings provide strong evidence for striatal CINs as a critical cellular target that may contribute to pathophysiology in children with rapid-onset OCD symptoms, and perhaps in other conditions.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Jian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry (Xu, Liu, Fahey, Frick, Duman, Williams, Pittenger), Child Study Center (Leckman, Vaccarino, Pittenger), Department of Pediatrics (Leckman), and Department of Neuroscience (Vaccarino), Yale University School of Medicine, New Haven, Conn.; Hunter James Kelly Research Institute, University at Buffalo, State University of New York, Buffalo (Frick); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School (Williams), Boston; Pediatrics and Developmental Neuroscience Branch, NIMH, Bethesda, Md. (Swedo); PANDAS Physicians Network (Swedo); and Interdepartmental Neuroscience Program, Yale University, New Haven, Conn. (Pittenger).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Rong-Jian</ForeName>
            <Initials>RJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry (Xu, Liu, Fahey, Frick, Duman, Williams, Pittenger), Child Study Center (Leckman, Vaccarino, Pittenger), Department of Pediatrics (Leckman), and Department of Neuroscience (Vaccarino), Yale University School of Medicine, New Haven, Conn.; Hunter James Kelly Research Institute, University at Buffalo, State University of New York, Buffalo (Frick); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School (Williams), Boston; Pediatrics and Developmental Neuroscience Branch, NIMH, Bethesda, Md. (Swedo); PANDAS Physicians Network (Swedo); and Interdepartmental Neuroscience Program, Yale University, New Haven, Conn. (Pittenger).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fahey</LastName>
            <ForeName>Shaylyn</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry (Xu, Liu, Fahey, Frick, Duman, Williams, Pittenger), Child Study Center (Leckman, Vaccarino, Pittenger), Department of Pediatrics (Leckman), and Department of Neuroscience (Vaccarino), Yale University School of Medicine, New Haven, Conn.; Hunter James Kelly Research Institute, University at Buffalo, State University of New York, Buffalo (Frick); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School (Williams), Boston; Pediatrics and Developmental Neuroscience Branch, NIMH, Bethesda, Md. (Swedo); PANDAS Physicians Network (Swedo); and Interdepartmental Neuroscience Program, Yale University, New Haven, Conn. (Pittenger).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frick</LastName>
            <ForeName>Luciana</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry (Xu, Liu, Fahey, Frick, Duman, Williams, Pittenger), Child Study Center (Leckman, Vaccarino, Pittenger), Department of Pediatrics (Leckman), and Department of Neuroscience (Vaccarino), Yale University School of Medicine, New Haven, Conn.; Hunter James Kelly Research Institute, University at Buffalo, State University of New York, Buffalo (Frick); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School (Williams), Boston; Pediatrics and Developmental Neuroscience Branch, NIMH, Bethesda, Md. (Swedo); PANDAS Physicians Network (Swedo); and Interdepartmental Neuroscience Program, Yale University, New Haven, Conn. (Pittenger).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leckman</LastName>
            <ForeName>James</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry (Xu, Liu, Fahey, Frick, Duman, Williams, Pittenger), Child Study Center (Leckman, Vaccarino, Pittenger), Department of Pediatrics (Leckman), and Department of Neuroscience (Vaccarino), Yale University School of Medicine, New Haven, Conn.; Hunter James Kelly Research Institute, University at Buffalo, State University of New York, Buffalo (Frick); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School (Williams), Boston; Pediatrics and Developmental Neuroscience Branch, NIMH, Bethesda, Md. (Swedo); PANDAS Physicians Network (Swedo); and Interdepartmental Neuroscience Program, Yale University, New Haven, Conn. (Pittenger).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vaccarino</LastName>
            <ForeName>Flora</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry (Xu, Liu, Fahey, Frick, Duman, Williams, Pittenger), Child Study Center (Leckman, Vaccarino, Pittenger), Department of Pediatrics (Leckman), and Department of Neuroscience (Vaccarino), Yale University School of Medicine, New Haven, Conn.; Hunter James Kelly Research Institute, University at Buffalo, State University of New York, Buffalo (Frick); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School (Williams), Boston; Pediatrics and Developmental Neuroscience Branch, NIMH, Bethesda, Md. (Swedo); PANDAS Physicians Network (Swedo); and Interdepartmental Neuroscience Program, Yale University, New Haven, Conn. (Pittenger).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duman</LastName>
            <ForeName>Ronald S</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry (Xu, Liu, Fahey, Frick, Duman, Williams, Pittenger), Child Study Center (Leckman, Vaccarino, Pittenger), Department of Pediatrics (Leckman), and Department of Neuroscience (Vaccarino), Yale University School of Medicine, New Haven, Conn.; Hunter James Kelly Research Institute, University at Buffalo, State University of New York, Buffalo (Frick); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School (Williams), Boston; Pediatrics and Developmental Neuroscience Branch, NIMH, Bethesda, Md. (Swedo); PANDAS Physicians Network (Swedo); and Interdepartmental Neuroscience Program, Yale University, New Haven, Conn. (Pittenger).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Williams</LastName>
            <ForeName>Kyle</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry (Xu, Liu, Fahey, Frick, Duman, Williams, Pittenger), Child Study Center (Leckman, Vaccarino, Pittenger), Department of Pediatrics (Leckman), and Department of Neuroscience (Vaccarino), Yale University School of Medicine, New Haven, Conn.; Hunter James Kelly Research Institute, University at Buffalo, State University of New York, Buffalo (Frick); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School (Williams), Boston; Pediatrics and Developmental Neuroscience Branch, NIMH, Bethesda, Md. (Swedo); PANDAS Physicians Network (Swedo); and Interdepartmental Neuroscience Program, Yale University, New Haven, Conn. (Pittenger).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Swedo</LastName>
            <ForeName>Susan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry (Xu, Liu, Fahey, Frick, Duman, Williams, Pittenger), Child Study Center (Leckman, Vaccarino, Pittenger), Department of Pediatrics (Leckman), and Department of Neuroscience (Vaccarino), Yale University School of Medicine, New Haven, Conn.; Hunter James Kelly Research Institute, University at Buffalo, State University of New York, Buffalo (Frick); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School (Williams), Boston; Pediatrics and Developmental Neuroscience Branch, NIMH, Bethesda, Md. (Swedo); PANDAS Physicians Network (Swedo); and Interdepartmental Neuroscience Program, Yale University, New Haven, Conn. (Pittenger).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pittenger</LastName>
            <ForeName>Christopher</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry (Xu, Liu, Fahey, Frick, Duman, Williams, Pittenger), Child Study Center (Leckman, Vaccarino, Pittenger), Department of Pediatrics (Leckman), and Department of Neuroscience (Vaccarino), Yale University School of Medicine, New Haven, Conn.; Hunter James Kelly Research Institute, University at Buffalo, State University of New York, Buffalo (Frick); Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School (Williams), Boston; Pediatrics and Developmental Neuroscience Branch, NIMH, Bethesda, Md. (Swedo); PANDAS Physicians Network (Swedo); and Interdepartmental Neuroscience Program, Yale University, New Haven, Conn. (Pittenger).</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 MH118453</GrantID>
            <Acronym>MH</Acronym>
            <Agency>NIMH NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 NS101104</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 MH109700</GrantID>
            <Acronym>MH</Acronym>
            <Agency>NIMH NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 MH119521</GrantID>
            <Acronym>MH</Acronym>
            <Agency>NIMH NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>06</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Am J Psychiatry</MedlineTA>
        <NlmUniqueID>0370512</NlmUniqueID>
        <ISSNLinking>0002-953X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C537163">Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Am J Psychiatry. 2021 Jan 1;178(1):5-7</RefSource>
          <PMID Version="1">33384008</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059329" MajorTopicYN="N">Cholinergic Neurons</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013290" MajorTopicYN="N">Streptococcal Infections</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Basal Ganglia</Keyword>
        <Keyword MajorTopicYN="Y">Cholinergic Interneuron</Keyword>
        <Keyword MajorTopicYN="Y">Interneuron</Keyword>
        <Keyword MajorTopicYN="Y">Obsessive-Compulsive Disorder</Keyword>
        <Keyword MajorTopicYN="Y">PANDAS</Keyword>
        <Keyword MajorTopicYN="Y">PANS</Keyword>
      </KeywordList>
      <CoiStatement>Disclosures. Dr. Pittenger has served as a consultant in the past year for Biohaven
Pharmaceuticals, Teva Pharmaceuticals, and Brainsway Therapeutics and has
performed research under contract with Biohaven and with Blackthorn
Therapeutics, Ltd., on unrelated projects. All other authors report no competing
interests. The authors have declared that no conflict of interest exists.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32539528</ArticleId>
        <ArticleId IdType="mid">NIHMS1745533</ArticleId>
        <ArticleId IdType="pmc">PMC8573771</ArticleId>
        <ArticleId IdType="doi">10.1176/appi.ajp.2020.19070698</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu HG, Lee CK, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wickramaratne PJ, et al.
The cross national epidemiology of obsessive compulsive disorder.
The Cross National Collaborative Group. J Clin
Psychiatry. 1994;55
Suppl:5–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8077177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the
National Comorbidity Survey Replication. Mol
Psychiatry.
2010;15:53–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2797569</ArticleId>
            <ArticleId IdType="pubmed">18725912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>SE S, JF L, NR R. From Research Subgroup to Clinical Syndrome: Modifying the
PANDAS Criteria to Describe PANS (Pediatric Acute-onset Neuropsychiatric
Syndrome).
2012;2:113.</Citation>
        </Reference>
        <Reference>
          <Citation>Singer HS, Gilbert DL, Wolf DS, Mink JW, Kurlan R. Moving from PANDAS to CANS. J
Pediatr.
2012;160:725–731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22197466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, Lougee L, Dow S, Zamkoff J, Dubbert BK. Pediatric autoimmune neuropsychiatric disorders
associated with streptococcal infections: clinical description of the first
50 cases. Am J Psychiatry.
1998;155:264–271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9464208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy TK, Patel PD, McGuire JF, Kennel A, Mutch PJ, Parker-Athill EC, Hanks CE, Lewin AB, Storch EA, Toufexis MD, Dadlani GH, Rodriguez CA. Characterization of the pediatric acute-onset
neuropsychiatric syndrome phenotype. J Child Adolesc
Psychopharmacol.
2015;25:14–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4340632</ArticleId>
            <ArticleId IdType="pubmed">25314221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang K, Frankovich J, Cooperstock M, Cunningham MW, Latimer ME, Murphy TK, Pasternack M, Thienemann M, Williams K, Walter J, Swedo SE. Clinical evaluation of youth with pediatric acute-onset
neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS
Consensus Conference. J Child Adolesc
Psychopharmacol.
2015;25:3–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4340805</ArticleId>
            <ArticleId IdType="pubmed">25325534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell
signaling in Sydenham chorea. Nat Med.
2003;9:914–920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12819778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirvan CA, Swedo SE, Kurahara D, Cunningham MW. Streptococcal mimicry and antibody-mediated cell
signaling in the pathogenesis of Sydenham’s chorea.
Autoimmunity.
2006;39:21–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16455579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swedo SE. Sydenham’s chorea. A model for childhood
autoimmune neuropsychiatric disorders.
JAMA.
1994;272:1788–1791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7661914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swedo SE, Rapoport JL, Cheslow DL, Leonard HL, Ayoub EM, Hosier DM, Wald ER. High prevalence of obsessive-compulsive symptoms in
patients with Sydenham’s chorea. Am J
Psychiatry.
1989;146:246–249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2912267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asbahr FR, Garvey MA, Snider LA, Zanetta DM, Elkis H, Swedo SE. Obsessive-compulsive symptoms among patients with
Sydenham chorea. Biol Psychiatry.
2005;57:1073–1076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15860349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witebsky E, Rose NR, Terplan K, Paine JR, Egan RW. Chronic thyroiditis and
autoimmunization. J Am Med Assoc.
1957;164:1439–1447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13448890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rose NR, Bona C. Defining criteria for autoimmune diseases
(Witebsky’s postulates revisited). Immunol
Today.
1993;14:426–430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8216719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirvan CA, Swedo SE, Snider LA, Cunningham MW. Antibody-mediated neuronal cell signaling in behavior
and movement disorders. J Neuroimmunol.
2006;179:173–179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16875742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirvan CA, Cox CJ, Swedo SE, Cunningham MW. Tubulin is a neuronal target of autoantibodies in
Sydenham’s chorea. J Immunol.
2007;178:7412–7421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17513792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben-Pazi H, Stoner JA, Cunningham MW. Dopamine receptor autoantibodies correlate with symptoms
in Sydenham’s chorea. PLoS One.
2013;8:e73516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3779221</ArticleId>
            <ArticleId IdType="pubmed">24073196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox CJ, Sharma M, Leckman JF, Zuccolo J, Zuccolo A, Kovoor A, Swedo SE, Cunningham MW. Brain human monoclonal autoantibody from sydenham chorea
targets dopaminergic neurons in transgenic mice and signals dopamine D2
receptor: implications in human disease. J
Immunol.
2013;191:5524–5541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3848617</ArticleId>
            <ArticleId IdType="pubmed">24184556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, Swedo SE. Therapeutic plasma exchange and intravenous
immunoglobulin for obsessive-compulsive disorder and tic disorders in
childhood. Lancet.
1999;354:1153–1158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10513708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garvey MA, Snider LA, Leitman SF, Werden R, Swedo SE. Treatment of Sydenham’s chorea with intravenous
immunoglobulin, plasma exchange, or prednisone. J
Child Neurol.
2005;20:424–429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15968928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams KA, Swedo SE, Farmer CA, Grantz H, Grant PJ, D’Souza P, Hommer R, Katsovich L, King RA, Leckman JF. Randomized, Controlled Trial of Intravenous
Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders
Associated With Streptococcal Infections. J Am Acad
Child Adolesc Psychiatry.
2016;55:860–867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27663941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sigra S, Hesselmark E, Bejerot S. Treatment of PANDAS and PANS: a systematic
review. Neurosci Biobehav Rev.
2018;86:51–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29309797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snider LA, Lougee L, Slattery M, Grant P, Swedo SE. Antibiotic prophylaxis with azithromycin or penicillin
for childhood-onset neuropsychiatric disorders. Biol
Psychiatry.
2005;57:788–792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15820236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garvey MA, Perlmutter SJ, Allen AJ, Hamburger S, Lougee L, Leonard HL, Witowski ME, Dubbert B, Swedo SE. A pilot study of penicillin prophylaxis for
neuropsychiatric exacerbations triggered by streptococcal
infections. Biol Psychiatry.
1999;45:1564–1571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10376116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurlan R, Kaplan EL. The pediatric autoimmune neuropsychiatric disorders
associated with streptococcal infection (PANDAS) etiology for tics and
obsessive-compulsive symptoms: hypothesis or entity? Practical
considerations for the clinician.
Pediatrics.
2004;113:883–886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15060240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaddanapudi K, Hornig M, Serge R, De Miranda J, Baghban A, Villar G, Lipkin WI. Passive transfer of streptococcus-induced antibodies
reproduces behavioral disturbances in a mouse model of pediatric autoimmune
neuropsychiatric disorders associated with streptococcal
infection. Mol Psychiatry.
2010;15:712–726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19668249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lotan D, Benhar I, Alvarez K, Mascaro-Blanco A, Brimberg L, Frenkel D, Cunningham MW, Joel D. Behavioral and neural effects of intra-striatal infusion
of anti-streptococcal antibodies in rats. Brain
Behav Immun.
2014;38:249–262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4000697</ArticleId>
            <ArticleId IdType="pubmed">24561489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pauls DL, Abramovitch A, Rauch SL, Geller DA. Obsessive-compulsive disorder: an integrative genetic
and neurobiological perspective. Nat Rev
Neurosci.
2014;15:410–424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24840803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez TV, Leckman JF, Pittenger C. Genetic susceptibility in obsessive-compulsive
disorder. Handb Clin Neurol.
2018;148:767–781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29478613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menzies L, Chamberlain SR, Laird AR, Thelen SM, Sahakian BJ, Bullmore ET. Integrating evidence from neuroimaging and
neuropsychological studies of obsessive-compulsive disorder: the
orbitofronto-striatal model revisited. Neurosci
Biobehav Rev.
2008;32:525–549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2889493</ArticleId>
            <ArticleId IdType="pubmed">18061263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bostan AC, Strick PL. The basal ganglia and the cerebellum: nodes in an
integrated network. Nat Rev Neurosci.
2018;19:338–350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6503669</ArticleId>
            <ArticleId IdType="pubmed">29643480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison BJ, Soriano-Mas C, Pujol J, Ortiz H, Lopez-Sola M, Hernandez-Ribas R, Deus J, Alonso P, Yucel M, Pantelis C, Menchon JM, Cardoner N. Altered corticostriatal functional connectivity in
obsessive-compulsive disorder. Arch Gen
Psychiatry.
2009;66:1189–1200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19884607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radua J, Mataix-Cols D. Voxel-wise meta-analysis of grey matter changes in
obsessive-compulsive disorder. Br J
Psychiatry.
2009;195:393–402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19880927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive
disorder: neurobiology, pathophysiology, and treatment.
Pharmacol Ther.
2011;132:314–332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3205262</ArticleId>
            <ArticleId IdType="pubmed">21963369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anticevic A, Hu S, Zhang S, Savic A, Billingslea E, Wasylink S, Repovs G, Cole MW, Bednarski S, Krystal JH, Bloch MH, Li CS, Pittenger C. Global resting-state functional magnetic resonance
imaging analysis identifies frontal cortex, striatal, and cerebellar
dysconnectivity in obsessive-compulsive disorder.
Biol Psychiatry.
2014;75:595–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3969771</ArticleId>
            <ArticleId IdType="pubmed">24314349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerfen CR, Bolam JP. The Neuroanatomical Organization of the Basal
Ganglia. Hbk Behav Neurosci.
2010;20:3–28.</Citation>
        </Reference>
        <Reference>
          <Citation>Kreitzer AC. Physiology and pharmacology of striatal
neurons. Annu Rev Neurosci.
2009;32:127–147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19400717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tepper JM, Bolam JP. Functional diversity and specificity of neostriatal
interneurons. Curr Opin Neurobiol.
2004;14:685–692.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15582369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apicella P
Leading tonically active neurons of the striatum from reward
detection to context recognition. Trends
Neurosci.
2007;30:299–306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17420057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burguiere E, Monteiro P, Mallet L, Feng G, Graybiel AM. Striatal circuits, habits, and implications for
obsessive-compulsive disorder. Curr Opin
Neurobiol.
2015;30:59–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4293232</ArticleId>
            <ArticleId IdType="pubmed">25241072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rapanelli M, Frick LR, Pittenger C. The Role of Interneurons in Autism and Tourette
Syndrome. Trends Neurosci.
2017;40:397–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5528854</ArticleId>
            <ArticleId IdType="pubmed">28578790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kataoka Y, Kalanithi PS, Grantz H, Schwartz ML, Saper C, Leckman JF, Vaccarino FM. Decreased number of parvalbumin and cholinergic
interneurons in the striatum of individuals with Tourette
syndrome. J Comp Neurol.
2010;518:277–291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2846837</ArticleId>
            <ArticleId IdType="pubmed">19941350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lennington JB, Coppola G, Kataoka-Sasaki Y, Fernandez TV, Palejev D, Li Y, Huttner A, Pletikos M, Sestan N, Leckman JF, Vaccarino FM. Transcriptome Analysis of the Human Striatum in Tourette
Syndrome. Biol Psychiatry.
2016;79:372–382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4305353</ArticleId>
            <ArticleId IdType="pubmed">25199956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalanithi PS, Zheng W, Kataoka Y, DiFiglia M, Grantz H, Saper CB, Schwartz ML, Leckman JF, Vaccarino FM. Altered parvalbumin-positive neuron distribution in
basal ganglia of individuals with Tourette syndrome.
Proc Natl Acad Sci U S A.
2005;102:13307–13312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1201574</ArticleId>
            <ArticleId IdType="pubmed">16131542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu M, Kobets A, Du JC, Lennington J, Li L, Banasr M, Duman RS, Vaccarino FM, DiLeone RJ, Pittenger C. Targeted ablation of cholinergic interneurons in the
dorsolateral striatum produces behavioral manifestations of Tourette
syndrome. Proc Natl Acad Sci U S A.
2015;112:893–898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4311862</ArticleId>
            <ArticleId IdType="pubmed">25561540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rapanelli M, Frick LR, Xu M, Groman SM, Jindachomthong K, Tamamaki N, Tanahira C, Taylor JR, Pittenger C. Targeted Interneuron Depletion in the Dorsal Striatum
Produces Autism-like Behavioral Abnormalities in Male but Not Female
Mice. Biol Psychiatry.
2017;82:194–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5374721</ArticleId>
            <ArticleId IdType="pubmed">28347488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frick LR, Rapanelli M, Jindachomthong K, Grant P, Leckman JF, Swedo S, Williams K, Pittenger C. Differential binding of antibodies in PANDAS patients to
cholinergic interneurons in the striatum. Brain
Behav Immun.
2018;69:304–311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5857467</ArticleId>
            <ArticleId IdType="pubmed">29233751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, Cicchetti D, Leckman JF. Children’s Yale-Brown Obsessive Compulsive Scale:
reliability and validity. J Am Acad Child Adolesc
Psychiatry.
1997;36:844–852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9183141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bateup HS, Svenningsson P, Kuroiwa M, Gong S, Nishi A, Heintz N, Greengard P. Cell type-specific regulation of DARPP-32
phosphorylation by psychostimulant and antipsychotic drugs.
Nat Neurosci.
2008;11:932–939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2737705</ArticleId>
            <ArticleId IdType="pubmed">18622401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rapanelli M, Frick L, Jindachomthong K, Xu J, Ohtsu H, Nairn AC, Pittenger C. Striatal Signaling Regulated by the H3R Histamine
Receptor in a Mouse Model of tic Pathophysiology.
Neuroscience.
2018;392:172–179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6204318</ArticleId>
            <ArticleId IdType="pubmed">30278251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ting JT, Daigle TL, Chen Q, Feng G. Acute brain slice methods for adult and aging animals:
application of targeted patch clamp analysis and
optogenetics. Methods Mol Biol.
2014;1183:221–242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4219416</ArticleId>
            <ArticleId IdType="pubmed">25023312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu RJ, Aghajanian GK. Stress blunts serotonin- and hypocretin-evoked EPSCs in
prefrontal cortex: role of corticosterone-mediated apical dendritic
atrophy. Proc Natl Acad Sci U S A.
2008;105:359–364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2224217</ArticleId>
            <ArticleId IdType="pubmed">18172209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rapanelli M, Frick LR, Horn KD, Schwarcz RC, Pogorelov V, Nairn AC, Pittenger C. The Histamine H3 Receptor Differentially Modulates
Mitogen-activated Protein Kinase (MAPK) and Akt Signaling in Striatonigral
and Striatopallidal Neurons. J Biol Chem.
2016;291:21042–21052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5076514</ArticleId>
            <ArticleId IdType="pubmed">27510032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim SA, Kang UJ, McGehee DS. Striatal cholinergic interneuron regulation and circuit
effects. Front Synaptic Neurosci.
2014;6:22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4204445</ArticleId>
            <ArticleId IdType="pubmed">25374536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzales KK, Smith Y. Cholinergic interneurons in the dorsal and ventral
striatum: anatomical and functional considerations in normal and diseased
conditions. Ann N Y Acad Sci.
2015;1349:1–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4564338</ArticleId>
            <ArticleId IdType="pubmed">25876458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martos YV, Braz BY, Beccaria JP, Murer MG, Belforte JE. Compulsive Social Behavior Emerges after Selective
Ablation of Striatal Cholinergic Interneurons. J
Neurosci.
2017;37:2849–2858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6596731</ArticleId>
            <ArticleId IdType="pubmed">28193688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bertran-Gonzalez J, Chieng BC, Laurent V, Valjent E, Balleine BW. Striatal cholinergic interneurons display
activity-related phosphorylation of ribosomal protein S6.
PLoS One.
2012;7:e53195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3532298</ArticleId>
            <ArticleId IdType="pubmed">23285266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knight ZA, Tan K, Birsoy K, Schmidt S, Garrison JL, Wysocki RW, Emiliano A, Ekstrand MI, Friedman JM. Molecular profiling of activated neurons by
phosphorylated ribosome capture. Cell.
2012;151:1126–1137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3839252</ArticleId>
            <ArticleId IdType="pubmed">23178128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pirbhoy PS, Farris S, Steward O. Synaptic activation of ribosomal protein S6
phosphorylation occurs locally in activated dendritic
domains. Learn Mem.
2016;23:255–269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4880148</ArticleId>
            <ArticleId IdType="pubmed">27194793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kovacevic M, Grant P, Swedo SE. Use of intravenous immunoglobulin in the treatment of
twelve youths with pediatric autoimmune neuropsychiatric disorders
associated with streptococcal infections. J Child
Adolesc Psychopharmacol.
2015;25:65–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4340809</ArticleId>
            <ArticleId IdType="pubmed">25658609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singer HS, Hong JJ, Yoon DY, Williams PN. Serum autoantibodies do not differentiate PANDAS and
Tourette syndrome from controls. Neurology.
2005;65:1701–1707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16207842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris CM, Pardo-Villamizar C, Gause CD, Singer HS. Serum autoantibodies measured by immunofluorescence
confirm a failure to differentiate PANDAS and Tourette syndrome from
controls. J Neurol Sci.
2009;276:45–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18823914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brilot F, Merheb V, Ding A, Murphy T, Dale RC. Antibody binding to neuronal surface in Sydenham chorea,
but not in PANDAS or Tourette syndrome.
Neurology.
2011;76:1508–1513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3087465</ArticleId>
            <ArticleId IdType="pubmed">21411742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dale RC, Merheb V, Pillai S, Wang D, Cantrill L, Murphy TK, Ben-Pazi H, Varadkar S, Aumann TD, Horne MK, Church AJ, Fath T, Brilot F. Antibodies to surface dopamine-2 receptor in autoimmune
movement and psychiatric disorders. Brain.
2012;135:3453–3468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23065479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nelson AB, Kreitzer AC. Reassessing models of basal ganglia function and
dysfunction. Annu Rev Neurosci.
2014;37:117–135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4416475</ArticleId>
            <ArticleId IdType="pubmed">25032493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanciego JL, Luquin N, Obeso JA. Functional neuroanatomy of the basal
ganglia. Cold Spring Harb Perspect Med.
2012;2:a009621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3543080</ArticleId>
            <ArticleId IdType="pubmed">23071379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding JB, Guzman JN, Peterson JD, Goldberg JA, Surmeier DJ. Thalamic gating of corticostriatal signaling by
cholinergic interneurons. Neuron.
2010;67:294–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4085694</ArticleId>
            <ArticleId IdType="pubmed">20670836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higley MJ, Gittis AH, Oldenburg IA, Balthasar N, Seal RP, Edwards RH, Lowell BB, Kreitzer AC, Sabatini BL. Cholinergic interneurons mediate fast VGluT3-dependent
glutamatergic transmission in the striatum. PLoS
One.
2011;6:e19155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3081336</ArticleId>
            <ArticleId IdType="pubmed">21544206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nelson AB, Hammack N, Yang CF, Shah NM, Seal RP, Kreitzer AC. Striatal cholinergic interneurons Drive GABA release
from dopamine terminals. Neuron.
2014;82:63–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3976769</ArticleId>
            <ArticleId IdType="pubmed">24613418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou FM, Liang Y, Dani JA. Endogenous nicotinic cholinergic activity regulates
dopamine release in the striatum. Nat
Neurosci.
2001;4:1224–1229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11713470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Threlfell S, Lalic T, Platt NJ, Jennings KA, Deisseroth K, Cragg SJ. Striatal dopamine release is triggered by synchronized
activity in cholinergic interneurons.
Neuron.
2012;75:58–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22794260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koos T, Tepper JM. Dual cholinergic control of fast-spiking interneurons in
the neostriatum. J Neurosci.
2002;22:529–535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6758683</ArticleId>
            <ArticleId IdType="pubmed">11784799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>English DF, Ibanez-Sandoval O, Stark E, Tecuapetla F, Buzsaki G, Deisseroth K, Tepper JM, Koos T. GABAergic circuits mediate the reinforcement-related
signals of striatal cholinergic interneurons. Nat
Neurosci.
2011;15:123–130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3245803</ArticleId>
            <ArticleId IdType="pubmed">22158514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faust TW, Assous M, Tepper JM, Koos T. Neostriatal GABAergic Interneurons Mediate Cholinergic
Inhibition of Spiny Projection Neurons. J
Neurosci.
2016;36:9505–9511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5013195</ArticleId>
            <ArticleId IdType="pubmed">27605623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faust TW, Assous M, Shah F, Tepper JM, Koos T. Novel fast adapting interneurons mediate
cholinergic-induced fast GABAA inhibitory postsynaptic currents in striatal
spiny neurons. Eur J Neurosci.
2015;42:1764–1774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4510010</ArticleId>
            <ArticleId IdType="pubmed">25865337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maeder-Ingvar M, Prior JO, Irani SR, Rey V, Vincent A, Rossetti AO. FDG-PET hyperactivity in basal ganglia correlating with
clinical course in anti-NDMA-R antibodies encephalitis.
J Neurol Neurosurg Psychiatry.
2011;82:235–236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20667855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turpin S, Martineau P, Levasseur MA, Meijer I, Decarie JC, Barsalou J, Renaud C, Decaluwe H, Haddad E, Lambert R. 18F-Flurodeoxyglucose positron emission tomography with
computed tomography (FDG PET/CT) findings in children with encephalitis and
comparison to conventional imaging. Eur J Nucl Med
Mol Imaging.
2019;46:1309–1324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30863933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleinig TJ, Thompson PD, Matar W, Duggins A, Kimber TE, Morris JG, Kneebone CS, Blumbergs PC. The distinctive movement disorder of ovarian
teratoma-associated encephalitis. Mov
Disord.
2008;23:1256–1261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18442127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR. Anti-NMDA-receptor encephalitis: case series and
analysis of the effects of antibodies. Lancet
Neurol.
2008;7:1091–1098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2607118</ArticleId>
            <ArticleId IdType="pubmed">18851928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohammad SS, Fung VS, Grattan-Smith P, Gill D, Pillai S, Ramanathan S, Brilot F, Dale RC. Movement disorders in children with anti-NMDAR
encephalitis and other autoimmune encephalopathies.
Mov Disord.
2014;29:1539–1542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25154478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blum P, Jankovic J. Stiff-person syndrome: an autoimmune
disease. Mov Disord.
1991;6:12–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2005917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geis C, Weishaupt A, Hallermann S, Grunewald B, Wessig C, Wultsch T, Reif A, Byts N, Beck M, Jablonka S, Boettger MK, Uceyler N, Fouquet W, Gerlach M, Meinck HM, Siren AL, Sigrist SJ, Toyka KV, Heckmann M, Sommer C. Stiff person syndrome-associated autoantibodies to
amphiphysin mediate reduced GABAergic inhibition.
Brain.
2010;133:3166–3180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20884644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujihara K. Neuromyelitis optica spectrum disorders: still evolving
and broadening. Curr Opin Neurol.
2019;32:385–394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6522202</ArticleId>
            <ArticleId IdType="pubmed">30893099</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
